| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.07 | 0.06 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.073 | 0.07 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.08 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.11 | 0.08 |